Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization

Vaccine

Volumn 19, Issue 7-8, 2000, Pages 850-861

  Shen, Xuzhuang ^a   Lagergård, Teresa ^a   Yang, Yonghong ^b   Lindblad, Marianne ^a   Fredriksson, Margareta ^a   Holmgren, Jan ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Conjugate vaccine; GBS type III CPS; Mucosal immunization

Indexed keywords

BACTERIAL POLYSACCHARIDE; CHOLERA TOXIN B SUBUNIT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONJUGATION; CONTROLLED STUDY; FEMALE; IMMUNIZATION; MOUSE; MUCOSAL IMMUNITY; NEWBORN INFECTION; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS AGALACTIAE; VACCINE PRODUCTION;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CHOLERA TOXIN; CHOLERA VACCINES; FEMALE; HUMANS; IMMUNITY, MUCOSAL; INFANT, NEWBORN; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED C57BL; POLYSACCHARIDES, BACTERIAL; PREGNANCY; SALMONELLA VACCINES; STREPTOCOCCAL VACCINES; STREPTOCOCCUS AGALACTIAE; VACCINES, CONJUGATE; VACCINES, SYNTHETIC;

EID: 0034703834     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00226-7     Document Type: Article

References (46)

1. Epidemiology of group B streptococcal disease in the United States: shifting paradigms
2. Epidemiology of group B streptococcal disease. Risk factors, prevention strategies, and vaccine development
3. Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. Maryland Emerging Infections Program
4. Antibody responses in invasive group B streptococcal infection in adults
5. Invasive group B streptococcal diseases in adults. A population-based study in metropolitan Atlanta [see comments]
6. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus
7. An oligosaccharide-tetanus toxoid conjugate vaccine against type III group B Streptococcus
8. Invasive group B streptococcal disease: the emergence of serotype V
9. Capsular polysaccharide type of group B streptococcal isolates from neonates with early-onset systemic infection
10. Experimental vaccination against Group B streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface protein Rib and α
11. Protein Rib: a novel group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections
12. Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes
13. Immunization of pregnant women with A polysaccharide vaccine of Group B streptococcus
14. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine
15. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib
16. Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine
17. Anti-capsular polysaccharide antibodies reduce nasopharyngeal colonization by Haemophilus influenzae type b in infant rats
18. Cervical secretions in pregnant women colonized rectally with group B streptococci have high levels of antibodies to serotype III polysaccharide capsular antigen and protein R
19. Nasal immunization with group B streptococci can induce high levels of specific IgA antibodies in cervicovaginal secretions of mice
20. Local and systemic antibody-cholera toxin B subunit conjugates
21. Antibody responses in serum and lung to intranasal immunization with Haemophilus influenzae type b polysaccharide conjugated to cholera toxin B subunit and tetanus toxoid
22. Anticarrier immunity suppresses the antibody response to polysaccharide antigens after intranasal immunization with the polysaccharide-protein conjugate
23. Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates
24. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina
25. Systemic and mucosal immune responses of mice to aluminium-adsorbed or aluminium-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B subunit
26. Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid
27. Monoclonal antibodies to Escherichia coli heat-labile enterotoxins: neutralizing activity and differentiation of human and porcine LTs and cholera toxin
28. Introduction of primary amine
29. Colorimetric method for determination of sugars and related substances
30. Stable thiobarbituric acid chromophore with dimethyl sulphoxide
31. An avidin-biotin based ELISA for quantitation of antibody to bacterial polysaccharides
32. Safety and immunogenicity of a tetravalent group B streptococcal polysaccharide vaccine in healthy adults
33. Immunogenicity of a Streptococcus pneumoniae type 4 polysaccharide-protein conjugate vaccine is decreased by admixture of high dose of free saccharide
34. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland
35. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates
36. Germinal center formation following immunization with the polysaccharide dextran B512 is substantially increased by cholera toxin
37. Immunogenicity of bacterial carbohydrates: cholera toxin modulates the immune response against dextran B512
38. Transdermal immunisation with cholera toxin induces both mucosal and systemic immunity [abstract]
39. Antigen recongnition in the female reproductive tract: I Uptake of intraluminal protein tracers in the mouse vagina
40. Estradiol and progesterone regulation of immunoglobulin A and G and secretory component in cervicovaginal secretions of the rat
41. Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues
42. Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance
43. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit
44. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes
45. Mucosal immunity and tolerance: relevance to vaccine development
46. Cholera toxin feeding did not induce oral tolerance in mice and abrogate oral tolerance to an unrelated protein antigen